{"id":"lyophilized-mepolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mepolizumab targets IL-5, a key cytokine involved in eosinophil development, recruitment, and survival. By neutralizing IL-5, the drug reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven inflammatory conditions such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:56.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"},{"name":"Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)"}]},"trialDetails":[{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT03562195","phase":"PHASE3","title":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-29","conditions":"Asthma","enrollment":300},{"nctId":"NCT04128371","phase":"PHASE2","title":"Mepolizumab in Episodic Angioedema With Eosinophilia","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-01-14","conditions":"Eosinophilia, Angioedema","enrollment":5},{"nctId":"NCT03298061","phase":"PHASE3","title":"Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-14","conditions":"Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT03055195","phase":"PHASE2","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-03-21","conditions":"Dermatitis, Atopic","enrollment":34},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT03014674","phase":"PHASE3","title":"A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-06","conditions":"Asthma","enrollment":246},{"nctId":"NCT02020889","phase":"PHASE3","title":"A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-05","conditions":"Churg-Strauss Syndrome","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lyophilized mepolizumab","genericName":"Lyophilized mepolizumab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}